Exit 156 Capital
Growth equityCollegeville · Growth–Late Stage · 3 people tracked
Investment thesis
Exit 156 Capital seeks non-controlling investments in companies scaling innovative business models in compelling markets. Its strategy centers on pairing distinctive, growth-oriented opportunities with strong financial expertise and a network of operating partners. The firm specializes in small and middle-market businesses that hold defensible market positions within healthcare services, devices, and technology. It follows a disciplined, people-focused investment philosophy, prioritizing strong and proven management teams where the firm can add value. A streamlined structure and flat operating model let the firm evaluate and close transactions quickly, forging aligned partnerships with managers focused on growth and success.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from the firm's website
What they invest in
from 5 of 6 portfolio companiesHealthtech ×5Digital Health ×2Medical Devices ×2SaaS ×2Deep Tech ×1HR Tech ×1
HQs:United States×2
Investments · 6 tracked
founders shown can be your intro pathBlue Wolf Body Sculpting offers awake liposuction, belly fat removal, and skin tightening procedures for body contouring in the Midwest.
HealthtechMidwest, US
Humla Health operates a matching platform connecting nurses directly with healthcare facilities to fill open shifts.
HealthtechHR TechSaaS
NightWare is a prescription digital therapeutic system for reducing sleep disturbance related to Nightmare Disorder and nightmares from post-traumatic stress disorder (PTSD), designed for adults 22 and older.
Digital HealthHealthtechMedical Devices
Matthew Tucker(Executive Officer, Director)Michael Ott(Director)Gerald Mattys(Director)Grady Hannah(Director)Michael Nathan(Executive Officer, Director)
UrgentIQ provides an AI-native electronic medical record and practice management system designed specifically for urgent care centers, handling patient intake, clinical documentation, coding, and billing.
Digital HealthHealthtechSaaSNew York, US
Nathaniel Gibbs(Executive Officer, Director, Promoter)Eric Slater(Executive Officer, Director, Promoter)
Vail Scientific develops VSNO, a portable breath analyzer that detects sepsis risk through exhaled nitric oxide measurement, enabling earlier screening for healthcare providers and hospitals.
Deep TechHealthtechMedical Devices
Frequently asked questions
- What stage does Exit 156 Capital invest at?
- Exit 156 Capital invests at the Growth, Late Stage stages.
- What sectors does Exit 156 Capital focus on?
- Exit 156 Capital focuses on Digital Health, Healthtech, Medical Devices.
- Where is Exit 156 Capital located?
- Exit 156 Capital is headquartered in Collegeville, US.
- Does Exit 156 Capital lead rounds?
- Exit 156 Capital typically participates in rounds rather than leading them.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital is a venture and growth investment firm that backs technology companies, including a dedicated Resilience Tech practice focused on energy, industrial and infrastructure systems.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.